Financial Performance and Losses - The company incurred net losses of €45.6 million, €46.1 million, and €42.7 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of €377.8 million as of December 31, 2025[54]. - The company expects to continue incurring significant net losses as it advances izicopan into additional clinical trials, with cash used for operating activities amounting to €35.3 million and €48.6 million for the years ended December 31, 2025, and 2024, respectively[55][61]. - The company anticipates needing substantial additional funding to continue its operations and may face delays or reductions in product development if unable to raise capital[61][64]. - The company may incur significant commercialization expenses related to product sales, marketing, and distribution if it obtains marketing approval for its product candidates[61]. - The company may face significant fluctuations in financial condition and operating results from quarter to quarter and year to year due to various uncontrollable factors[69]. Regulatory Approvals and Market Authorization - The company received Emergency Use Authorization (EUA) for GOHIBIC (vilobelimab) in the United States in April 2023 and market authorization in Europe in January 2025[66]. - The company has not yet received marketing approval for any product candidates, which poses a risk to future revenue generation[99]. - The marketing approval process is lengthy and uncertain, with no current applications submitted for any product candidates in the U.S. or other jurisdictions[98]. - The company is not permitted to market any product candidates without obtaining necessary marketing approvals from regulatory authorities[76]. - The company received Emergency Use Authorization (EUA) for GOHIBIC (vilobelimab) in April 2023, but it remains subject to ongoing regulatory oversight[78]. Clinical Trials and Development Risks - The clinical development of product candidates is subject to significant risks, including potential failure at any stage, which may delay regulatory approval for years[88]. - Inability to complete clinical trials could lead to additional costs and impair revenue generation from product sales and milestones[89]. - Failure to demonstrate safety and efficacy in clinical trials would significantly harm the company's business prospects[90]. - Patient enrollment in clinical trials is critical, and difficulties in this area could delay development and revenue generation[104]. - The company acknowledges that delays in clinical trials could significantly increase product development costs and impair commercialization efforts[125]. Intellectual Property and Patent Risks - The success of the company depends on obtaining and maintaining intellectual property protection for its product candidates, which is a complex and costly process[178]. - The patent position of the company may be uncertain, and challenges to patents could limit the ability to prevent competitors from commercializing similar products[180]. - The company’s patent portfolio consists of six families of patents related to C5a and C5aR inhibitors, but the breadth of claims that may be allowed or enforced is unpredictable[192]. - The company cannot assure that any of its patent applications will be found patentable, which could limit its competitive advantage[193]. - The company may struggle to enforce its intellectual property rights globally due to varying patent laws and enforcement challenges in different jurisdictions[212]. Manufacturing and Supply Chain Risks - The company relies on third-party manufacturers for the clinical and commercial supply of vilobelimab, which introduces risks related to political and economic disruptions, particularly in China[159]. - Manufacturing biologics like vilobelimab is highly susceptible to product loss due to contamination, equipment failure, and other risks, which could lead to significant delays in development programs[164]. - The manufacturing process is subject to quality control risks, and any failure to comply with cGMP standards could adversely affect the company's operations and financial results[165]. - The inability of third-party manufacturers to scale production or optimize yield may increase manufacturing costs and delay commercialization[169]. - The company may incur additional costs and delays if it needs to secure alternative supply arrangements for its products[160]. Competition and Market Challenges - Market acceptance by physicians and patients is crucial for commercial success, and existing therapies may hinder the adoption of new products[107]. - The company faces challenges in obtaining adequate reimbursement levels from third-party payors, which could affect pricing and demand for its products[112]. - The company may face significant uncertainty related to third-party payor coverage and reimbursement for newly approved drugs, which could impact revenue generation[114]. - The company is focusing on developing product candidates for specific indications deemed most likely to succeed, potentially foregoing other profitable opportunities[120]. - Competition for collaboration agreements is significant, and the success of these collaborations will depend on various factors including the differentiation of product candidates and regulatory approval likelihood[171]. Employee and Operational Risks - As of December 31, 2025, the company had 65 full-time or part-time employees, indicating limited resources for operations and development[225]. - The biotechnology and pharmaceuticals industry has experienced high turnover rates, which could hinder the company's ability to implement its business strategy successfully[227]. - The company faces intense competition for hiring qualified personnel, which may limit its ability to attract and retain key employees[228]. - Misconduct by employees, contractors, or consultants could lead to significant liability and harm the company's reputation[231]. - The company relies heavily on its executive officers and directors, and their loss could materially harm business operations[226]. Financial Market and Shareholder Risks - The trading price of the company's ordinary shares has been highly volatile, influenced by various factors including clinical trial results and regulatory actions[232]. - Future sales of a substantial number of ordinary shares could adversely affect the share price and dilute existing shareholders[234]. - The company has an at-the-market program for the sale of ordinary shares with an aggregate offering price of up to $75 million, which may impact share price[234]. - The company has registered ordinary shares under its equity incentive plans, allowing for potential dilution if these shares are sold in the public market[235]. - The company must maintain and renew its operational structure to avoid disruptions, which requires significant capital expenditure[230].

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.86%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.16, delivering no surprise.Over the last four quarters, the company has surpassed consensu ...

Core Viewpoint - InflaRx N.V. is focusing its resources on izicopan, an anti-inflammatory therapeutic, following positive Phase 2a results in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [2][3] Financial Results - For the year ended December 31, 2025, InflaRx reported a net loss of €45.6 million, or €0.68 per ordinary share, compared to a net loss of €46.1 million, or €0.78 per ordinary share, for 2024 [20] - Total funds available as of December 31, 2025, amounted to approximately €46.2 million, which includes €16.0 million in cash and cash equivalents and €30.2 million in marketable securities [21] - Marketing and sales expenses decreased by €2.3 million to €4.5 million for the year ended December 31, 2025, primarily due to lower external service costs [15] - Research and development expenses decreased by €9.6 million to €25.7 million, mainly due to lower costs from manufacturing development activities and clinical trials [16] Business Update - InflaRx is in active discussions with the FDA regarding the design of a Phase 2b trial for izicopan in HS and expects to finalize communications soon [2][3] - The company plans to conduct a pharmacokinetic bridging study in China to expedite proof-of-concept studies for izicopan in additional indications [6] - InflaRx aims to host a virtual Capital Markets Day to provide insights into izicopan's clinical development path and market opportunities [4] Clinical Development - Izicopan has shown promising Phase 2a data, indicating rapid and meaningful reductions in abscesses and nodules in HS, with improvements in various clinical measures [7][9] - In CSU, izicopan demonstrated improvements in clinical measures that exceed historical placebo levels, particularly in patients with severe disease [10] - The company is considering further development of izicopan in CSU, with a potential market opportunity exceeding $1 billion [10] Pipeline and Strategy - InflaRx is reviewing additional development opportunities for izicopan in ANCA-associated vasculitis (AAV), highlighting its best-in-class potential due to its differentiated safety profile [5][8] - The company is actively engaging with potential collaborators to expedite its pipeline development goals [8]

Core Insights - InflaRx N.V. announced an oral presentation of its Phase 3 study data for vilobelimab in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting [1][2] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary anti-C5a and anti-C5aR technologies to develop specific inhibitors targeting the complement activation factor C5a and its receptor C5aR [3] - The company's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies [3] - InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [3] Upcoming Presentation Details - The oral presentation titled "Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial" will be presented by Dr. Benjamin Kaffenberger on March 28, 2026, from 2:24 to 2:36 PM MT at the Bellco Theatre 3 [2]

InflaRx (IFRX) said on Friday it had received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement after its shares closed below that level for 30 consecutive business days. ...

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [2] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [2] Product Development - Izicopan is being developed for the treatment of several inflammatory diseases, including hidradenitis suppurativa [2] - The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [2] Financial Information - InflaRx will publish its financial and operating results for the fourth quarter and full year 2025 on March 19, 2026, before the market opens [1]

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx (NasdaqGS: IFRX) - **Focus**: Development of izicopan, a C5AR molecule inhibitor, for various immunological conditions, including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1][2] Key Points Drug Development and Pipeline - **Izicopan**: Positioned as a best-in-class potential drug targeting the complement terminal pathway, which is significant in various immunological diseases [1] - **Clinical Trials**: Completed a Phase 2a trial for izicopan in HS and CSU, with promising early efficacy signals [2][5] - **Regulatory Discussions**: Ongoing discussions with the FDA regarding the regulatory path and potential new endpoints for clinical trials [2][13] Efficacy Data - **HS Data**: The drug showed a significant reduction in lesions and draining tunnels, with 50% of patients in the high-dose group free of draining tunnels after four weeks [7][8] - **Pain Reduction**: Notable pain reduction was reported across all dosing groups, which is a critical factor for patient quality of life [5][8] - **HiSCR Endpoint Issues**: The current HiSCR endpoint has shown variability in placebo responses, complicating trial outcomes. A modified HiSCR endpoint is being discussed with the FDA [12][22] Market Opportunities - **ANCA Vasculitis**: InflaRx is exploring opportunities in ANCA vasculitis, a serious condition with significant unmet medical needs [3][34] - **Avacopan Market Dynamics**: The potential withdrawal of avacopan from the market due to safety concerns presents an opportunity for izicopan, which does not share the same liver toxicity issues [36][41] Financial Position and Strategy - **Funding**: The company is funded into mid-2027 and is exploring collaborations with pharmaceutical companies to expand the potential applications of izicopan [32][33] - **Capital Markets Day**: An upcoming event is expected to provide clarity on the development path for HS and other indications, as well as potential collaborations [30] Future Directions - **Exploratory Studies**: Initiating PK bridging studies in China to facilitate faster and more cost-effective data generation for different indications [59][60] - **Focus on CSU**: Despite mixed results in CSU, there is a belief in the drug's potential, particularly in severe cases, and plans to further explore this indication as funding allows [56] Additional Insights - **Regulatory Challenges**: The company acknowledges the complexities of trial design and the need for larger patient cohorts to achieve statistically significant results [20][22] - **Collaborative Efforts**: Engaging with other companies to explore alternative indications and enhance the drug's market potential [58] This summary encapsulates the critical aspects of InflaRx's current status, drug development efforts, market opportunities, and strategic direction as discussed in the conference call.

JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside ch ...

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx - **Focus**: Biopharmaceutical company specializing in anti-C5a and C5a inhibitors for inflammatory diseases, including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1][2] Core Points and Arguments Drug Development - **Izicopan**: A new oral inhibitor targeting C5a receptor 1, showing biologic-like efficacy in HS and CSU [3] - **Mechanism**: High potency on target engagement, with potential to be transformative in anti-inflammatory diseases [3] - **Pipeline**: Focused on broader inflammatory and immunology (I&I) space, with cash funding until mid-2027 [4] Competitive Positioning - **Best-in-Class Potential**: Studies indicate izicopan has a differentiated pharmacokinetic (PK) profile compared to marketed comparator avacopan, showing a 10x increase in area under the curve and a 3x higher peak [12][13] - **Safety Profile**: Izicopan has a 36-fold less engagement with CYP3A4/5, reducing the risk of liver toxicity [14] Clinical Trials and Results - **Phase II Study**: Completed in HS and CSU, showing significant reductions in abscess and inflammatory nodules, particularly in the high-dose group [19][24] - **Draining Tunnels**: 50% of patients in the high-dose group achieved zero draining tunnels by week four, indicating a meaningful early response [27] - **Pain Reduction**: Notable improvements in skin pain, with up to 75% of patients achieving a 30% improvement on the numeric rating scale [31] Market Opportunity - **ANCA-Associated Vasculitis**: Estimated market potential of over $1 billion, with current sales around $700 million globally [41] - **Differentiated Label Potential**: Opportunity to position izicopan as corticosteroid-sparing due to its unique mechanism and safety profile [42][43] Future Directions - **Regulatory Discussions**: Active discussions with the FDA regarding the development path for izicopan, with updates expected in spring [34] - **Chronic Spontaneous Urticaria**: Initial data shows promise, but HS remains the primary focus for development [36] Additional Important Content - **Patient Impact**: Emphasis on the significant social and physical burden of HS, highlighting the need for effective treatments [20] - **Comparative Analysis**: Izicopan's early efficacy in reducing draining tunnels and pain is positioned favorably against existing treatments [32][33] - **Long-term Efficacy**: Continued improvement in symptoms observed even after cessation of treatment, indicating potential for sustained benefits [30] This summary encapsulates the key points discussed during the conference call, focusing on InflaRx's strategic direction, drug development, clinical results, and market opportunities.

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx - **Industry**: Biotechnology - **Headquarters**: Germany and the U.S. - **IPO**: Listed on NASDAQ in 2017 - **Focus**: Development of drugs targeting terminal complement inhibition, specifically C5a and C5a receptor 1 Key Molecules - **Vilobelimab**: Antibody targeting C5a - **Izicopan**: Small molecule targeting C5a receptor 1 - Recently completed a positive proof of concept Phase 2a study [2][5] Differentiation of Izicopan - **Pharmacological Properties**: - Higher bioavailability and plasma levels compared to avacopan (Amgen's drug) - Faster onset of receptor inhibition, achieving peak levels in days versus avacopan's 13 weeks [5][6] - Significantly lower inhibition of CYP3A4, reducing potential drug-drug interactions [6] - **Safety Profile**: - No observed hepatotoxicity in 200 treated patients, contrasting with avacopan's reported issues [8][9] Market Opportunities - **Potential Market Impact**: If avacopan were withdrawn, InflaRx sees an opportunity to position izicopan favorably [13] - **Hidradenitis Suppurativa (HS)**: - Conducted a 28-day study showing promising results, including reduction of draining tunnels and pain [15][16] - Data compared favorably to existing treatments, indicating a potential best-in-class profile [27] Future Development Plans - **Next Steps**: - Planning a Phase 2B study, as the initial four-week trial does not suffice for pivotal trials [23] - Ongoing discussions with the FDA regarding dosing and trial design [21][25] - **Capital Markets Day**: Expected in spring, with disclosures on HS and other indications [24][36] Financial Position - **Cost Reduction**: Fixed costs reduced by approximately 30% due to the deprioritization of vilobelimab and related activities [33] Additional Indications - **Chronic Spontaneous Urticaria (CSU)**: Encouraging data suggests potential for further trials, contingent on resources [30][32] Conclusion InflaRx is positioned to leverage its differentiated drug izicopan in the competitive landscape of autoimmune diseases, particularly HS and potentially CSU, while maintaining a strong safety profile and reducing operational costs. The upcoming Capital Markets Day will provide further insights into their strategic direction and clinical development plans.